Adenosine A 2B receptor agonism inhibits neointimal lesion development after arterial injury in apolipoprotein E-deficient mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 9, 2012, Pages 2197-2205

  Bot, Ilze ^a   De Vries, Henk ^a   Korporaal, Suzanne J A ^a   Foks, Amanda C ^a   Bot, Martine ^a   Van Veldhoven, Jacobus ^a   Ter Borg, Mariëtte N D ^a   Van Santbrink, Peter J ^a   Van Berkel, Theo J C ^a   Kuiper, Johan ^a   Ijzerman, Adriaan P ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

A 2B receptor; adenosine; agonist; restenosis; smooth muscle cell proliferationAdenosine

Indexed keywords

ADENOSINE A2B RECEPTOR; ADENOSINE A2B RECEPTOR AGONIST; ADENOSINE RECEPTOR STIMULATING AGENT; ANTIMITOTIC AGENT; APOLIPOPROTEIN E; BAY 60 6583; COLLAGEN; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR AGONIST; AMINOPYRIDINE DERIVATIVE; BAY 60-6583; CARDIOVASCULAR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTERY OCCLUSION; ARTICLE; CAROTID ARTERY; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; IN VITRO STUDY; MACROPHAGE; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; SMOOTH MUSCLE FIBER; TREATMENT RESPONSE; VASCULAR SMOOTH MUSCLE; ANIMAL; CAROTID ARTERY INJURY; CAROTID ARTERY OBSTRUCTION; CELL ADHESION; CELL STRAIN HEK293; CHO CELL; COMMON CAROTID ARTERY; CRICETULUS; DISEASE MODEL; DRUG EFFECT; FAT INTAKE; GENETIC TRANSFECTION; GENETICS; HAMSTER; HUMAN; INJURY; LEUKOCYTE ACTIVATION; METABOLISM; MOUSE MUTANT; NEUTROPHIL; PATHOLOGY; THROMBOCYTE ACTIVATION; TIME; VASCULAR ENDOTHELIUM;

ADENOSINE A2 RECEPTOR AGONISTS; AMINOPYRIDINES; ANIMALS; APOLIPOPROTEINS E; CARDIOVASCULAR AGENTS; CAROTID ARTERY INJURIES; CAROTID ARTERY, COMMON; CAROTID STENOSIS; CELL ADHESION; CELL PROLIFERATION; CHO CELLS; COLLAGEN; CRICETINAE; CRICETULUS; DIETARY FATS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; HEK293 CELLS; HUMANS; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; NEUTROPHIL ACTIVATION; NEUTROPHILS; PLATELET ACTIVATION; RECEPTOR, ADENOSINE A2B; TIME FACTORS; TRANSFECTION;

EID: 84865470000     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.252924     Document Type: Article

References (38)

1. Blackburn MR, Vance CO, Morschl E, Wilson CN. Adenosine receptors and inflammation. Handb Exp Pharmacol. 2009;193:215-269.
2. Ponnoth DS, Jamal Mustafa S. Adenosine receptors and vascular inflammation. Biochim Biophys Acta. 2011;1808:1429-1434.
3. Caruso M, Varani K, Tringali G, Polosa R. Adenosine and adenosine receptors: their contribution to airway inflammation and therapeutic potential in asthma. Curr Med Chem. 2009;16:3875-3885.
4. Varani K, Padovan M, Govoni M, Vincenzi F, Trotta F, Borea PA. The role of adenosine receptors in rheumatoid arthritis. Autoimmun Rev. 2010;10:61-64.
5. Haskó G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008;7:759-770.
6. Ham J, Rees DA. The adenosine a2b receptor: its role in inflammation. Endocr Metab Immune Disord Drug Targets. 2008;8:244-254.
7. Aherne CM, Kewley EM, Eltzschig HK. The resurgence of A2B adenosine receptor signaling. Biochim Biophys Acta. 2011;1808:1329-1339.
8. Ryzhov S, Zaynagetdinov R, Goldstein AE, Novitskiy SV, Blackburn MR, Biaggioni I, Feoktistov I. Effect of A2B adenosine receptor gene ablation on adenosine-dependent regulation of proinflammatory cytokines. J Pharmacol Exp Ther. 2008;324:694-700.
9. Belikoff BG, Hatfield S, Georgiev P, Ohta A, Lukashev D, Buras JA, Remick DG, Sitkovsky M. A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice. J Immunol. 2011;186:2444-2453.
10. Ryzhov S, Goldstein AE, Matafonov A, Zeng D, Biaggioni I, Feoktistov I. Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: an A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J Immunol. 2004;172:7726-7733.
11. Yang D, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M, Jones MR, St Hilaire C, Seldin DC, Toselli P, Lamperti E, Schreiber BM, Gavras H, Wagner DD, Ravid K. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest. 2006;116:1913-1923.
12. Koupenova M, Johnston-Cox H, Vezeridis A, Gavras H, Yang D, Zannis V, Ravid K. A2b adenosine receptor regulates hyperlipidemia and atherosclerosis. Circulation. 2012;125:354-363.
13. Yang D, Koupenova M, McCrann DJ, Kopeikina KJ, Kagan HM, Schreiber BM, Ravid K. The A2B adenosine receptor protects against vascular injury. Proc Natl Acad Sci USA. 2008;105:792-796.
14. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptors. Hypertension. 1998;31(1 Pt 2):516-521.
15. Kent KM. Restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1988;61:67G-70G.
16. Chesebro JH, Lam JY, Fuster V. The pathogenesis and prevention of aortocoronary vein bypass graft occlusion and restenosis after arterial angioplasty: role of vascular injury and platelet thrombus deposition. J Am Coll Cardiol. 1986;8:57B-66B.
17. Liu MW, Roubin GS, King SB 3rd. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation. 1989;79:1374-1387.
18. Marx SO, Totary-Jain H, Marks AR. Vascular smooth muscle cell proliferation in restenosis. Circ Cardiovasc Interv. 2011;4:104-111.
19. Baraldi PG, Tabrizi MA, Fruttarolo F, Romagnoli R, Preti D. Recent improvements in the development of A(2B) adenosine receptor agonists. Purinergic Signal. 2008;4:287-303.
20. Eckle T, Krahn T, Grenz A, Köhler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, Eltzschig HK. Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation. 2007;115:1581-1590.
21. Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, Eltzschig HK. A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood. 2008;111:2024-2035.
22. Chang LC, von Frijtag Drabbe Künzel JK, Mulder-Krieger T, Spanjersberg RF, Roerink SF, van den Hout G, Beukers MW, Brussee J, Ijzerman AP. A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor. J Med Chem. 2005;48:2045-2053.
23. Zernecke A, Schober A, Bot I, von Hundelshausen P, Liehn EA, Möpps B, Mericskay M, Gierschik P, Biessen EA, Weber C. SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res. 2005;96:784-791.
24. Zernecke A, Bidzhekov K, Ozüyaman B, Fraemohs L, Liehn EA, Lüscher-Firzlaff JM, Lüscher B, Schrader J, Weber C. CD73/ecto-5'-nucleotidase protects against vascular inflammation and neointima formation. Circulation. 2006;113:2120-2127.
25. Yang D, Chen H, Koupenova M, Carroll SH, Eliades A, Freedman JE, Toselli P, Ravid K. A new role for the A2b adenosine receptor in regulating platelet function. J Thromb Haemost. 2010;8:817-827.
26. Soehnlein O, Wantha S, Simsekyilmaz S, et al. Neutrophil-derived cathelicidin protects from neointimal hyperplasia. Sci Transl Med. 2011;3:103ra98.
27. Jackson EK, Ren J, Gillespie DG, Dubey RK. Extracellular 2',3'-cyclic adenosine 5'-monophosphate is a potent inhibitor of preglomerular vascular smooth muscle cell and mesangial cell growth. Hypertension. 2010;56:151-158.
28. Jackson EK, Gillespie DG, Dubey RK. 2'-AMP and 3'-AMP inhibit proliferation of preglomerular vascular smooth muscle cells and glomerular mesangial cells via A2B receptors. J Pharmacol Exp Ther. 2011;337:444-450.
29. Auchampach JA, Kreckler LM, Wan TC, Maas JE, van der Hoeven D, Gizewski E, Narayanan J, Maas GE. Characterization of the A2B adenosine receptor from mouse, rabbit, and dog. J Pharmacol Exp Ther. 2009;329:2-13.
30. van der Hoeven D, Wan TC, Gizewski ET, Kreckler LM, Maas JE, Van Orman J, Ravid K, Auchampach JA. A role for the low-affinity A2B adenosine receptor in regulating superoxide generation by murine neutrophils. J Pharmacol Exp Ther. 2011;338:1004-1012.
31. Sobue K, Hayashi K, Nishida W. Expressional regulation of smooth muscle cell-specific genes in association with phenotypic modulation. Mol Cell Biochem. 1999;190:105-118.
32. Regan CP, Adam PJ, Madsen CS, Owens GK. Molecular mechanisms of decreased smooth muscle differentiation marker expression after vascular injury. J Clin Invest. 2000;106:1139-1147.
33. van Tiel CM, Bonta PI, Rittersma SZ, Beijk MA, Bradley EJ, Klous AM, Koch KT, Baas F, Jukema JW, Pons D, Sampietro ML, Pannekoek H, de Winter RJ, de Vries CJ. p27kip1-838C>A single nucleotide polymorphism is associated with restenosis risk after coronary stenting and modulates p27kip1 promoter activity. Circulation. 2009;120:669-676.
34. Xaus J, Valledor AF, Cardó M, Marquès L, Beleta J, Palacios JM, Celada A. Adenosine inhibits macrophage colony-stimulating factor-dependent proliferation of macrophages through the induction of p27kip-1 expression. J Immunol. 1999;163:4140-4149.
35. Dubey RK, Gillespie DG, Jackson EK. Adenosine inhibits collagen and total protein synthesis in vascular smooth muscle cells. Hypertension. 1999;33(1 Pt 2):190-194.
36. Terkeltaub R, Boisvert WA, Curtiss LK. Chemokines and atherosclerosis. Curr Opin Lipidol. 1998;9:397-405.
37. Dai Y, Zhang W, Wen J, Zhang Y, Kellems RE, Xia Y. A2B adenosine receptor-mediated induction of IL-6 promotes CKD. J Am Soc Nephrol. 2011;22:890-901.
38. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev. 2011;63:1-34.